Novo Nordisk Aktie
| 97,97EUR | -1,06EUR | -1,07% |
WKN DE: A3EU6F / ISIN: DK0062498333
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 93,90 |
| Novo Holdings A/S (Investment Company) | 5,61 |
| American Funds EuroPacific Growth Fund | 1,42 |
| Government Pension Fund - Global (The) | 1,40 |
| Vanguard Total International Stock Index Fund | 1,27 |
| American Funds New Perspective Fund | 0,93 |
| Vanguard Developed Markets Index Fund | 0,78 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 43 258 | 45 323 | 47 792 | 54 393 | 63 370 |
| Umsatz pro Mitarbeiter in Mio. EUR | 2,82 | 2,80 | 2,95 | 3,25 | 3,67 |
Bilanz (in Mio. DKK) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 62 456 | 65 809 | 85 595 | 108 194 | 139 646 |
| Summe Anlagevermögen | 63 156 | 79 113 | 108 913 | 133 063 | 174 840 |
| Summe Aktiva | 125 612 | 144 922 | 194 508 | 241 257 | 314 486 |
Bilanz (in Mio. DKK) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 4 483 | 10 356 | 26 645 | 25 784 | 27 006 |
| Summe Fremdkapital | 68 019 | 81 597 | 123 762 | 157 771 | 207 925 |
| Summe Eigenkapital | 57 593 | 63 325 | 70 746 | 83 486 | 106 561 |
| Summe Passiva | 125 612 | 144 922 | 194 508 | 241 257 | 314 486 |
Adresse
| Novo Allé 1, 2880 Bagsværd | |
| Internet | http://www.novonordisk.com |
Management
|
Andreas Fibig
Independent Director |
|
Camilla Sylvest
EVP-Commercial Strategy & Corporate Affairs |
|
Christina Law
Independent Director |
|
Daniel Bohsen
Vice President & Head-Investor Relations |
|
Douglas Langa
EVP & Head-North America Operations |
|
Elisabeth Dahl Christensen
Non-Independent Director |
|
Helge Lund
Chairman |
|
Henrik Ehlers Wulff
Executive VP-Product Supply, Quality & IT |
|
Henrik Poulsen
Vice Chairman |
|
Irina Ivanischeva
Vice President & General Manager |
|
Jane Buus Laursen
Corporate Vice President |
|
Karsten Munk Knudsen
Chief Financial Officer & Executive Vice President |
|
Kasim Kutay
Non-Independent Director |
|
Kristine Færch
Project Director-Data Science |
|
Lars Fruergaard Jørgensen
President & Chief Executive Officer |
|
Laurence Debroux
Independent Director |
|
Liselotte Hyveled
Chief Patient Officer & Non-Independent Director |
|
Ludovic Helfgott
Executive Vice President & Head-Biopharm |
|
Marcus Schindler
Chief Scientific Officer & Executive VP-Research |
|
Martin Holst Lange
Executive Vice President-Development |
|
Martin W. MacKay
Independent Director |
|
Maziar Mike Doustdar
Executive Vice President-International Operations |
|
Mette Bøjer Jensen
Non-Independent Director |
|
Mette Zacho
Vice President |
|
Robin Evers
Senior VP & Head-Global Regulatory Affairs |
|
Sergey Manelis
Commercial Director |
|
Stephen Gough
Global Chief Medical Officer |
|
Sylvie Louise Grégoire
Independent Director |
|
Tania Sabroe
Executive VP-Global People & Organisation |
|
Thomas Rantzau
Non-Independent Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
